This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Kymera's Eczema Drug Gets Fast Track Designation in the United States
by Zacks Equity Research
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
SNYPositive Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
by Zacks Equity Research
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
GSKPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
by Sundeep Ganoria
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
JNJPositive Net Change AMGNPositive Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
by Zacks Equity Research
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
GSKPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs medical
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
by Kanishka Das
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
by Zacks Equity Research
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
RHHBYNegative Net Change LLYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
by Ahan Chakraborty
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
NVOPositive Net Change LLYPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ANIP stock based on the movements in the options market lately.
ANIPPositive Net Change
biotechnology biotechs medical
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
by Zacks Equity Research
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
NVOPositive Net Change LLYPositive Net Change WVEPositive Net Change
biotechs medical pharmaceuticals
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
by Sundeep Ganoria
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Best Cheap Stocks Under $10 to Buy in December and 2026
by Benjamin Rains
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
FOLDPositive Net Change
biotechs
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
by Zacks Equity Research
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
SNYPositive Net Change ANIPPositive Net Change CSTLNegative Net Change KYMRNegative Net Change
biotechs
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
by Zacks Equity Research
AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
AGIOPositive Net Change ANIPPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBPositive Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
ANIPPositive Net Change CRMDPositive Net Change ARQTPositive Net Change PRAXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
by Zacks Equity Research
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
INCYNegative Net Change ANIPPositive Net Change CRMDPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
by Zacks Equity Research
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
ANIPPositive Net Change CRMDPositive Net Change ARQTPositive Net Change ABSIPositive Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
by Zacks Equity Research
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
ANIPPositive Net Change CRMDPositive Net Change CAPRPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech ETF (XBI) Hits New 52-Week High
by Zacks Equity Research
XBI hits a 52-week high, climbing 85% from its low, as biotech gains momentum from AI adoption and favorable market trends.
XBIPositive Net Change
biotechs etfs
Can Galafold Continue to Drive Amicus' Top Line in 2026?
by Kanishka Das
FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.
SNYPositive Net Change TEVAPositive Net Change FOLDPositive Net Change
biotechs
Denali Enters Into a $275M Funding Deal With Royalty Pharma
by Ekta Bagri
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
BIIBPositive Net Change RPRXNegative Net Change DNLIPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
by Ekta Bagri
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
NVSNegative Net Change BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
by Kanishka Das
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
PFEPositive Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs